Name two CGRP pathway blocking agents approved for migraine prevention and their general mode of administration.

Name two CGRP pathway blocking agents approved for migraine prevention and their general mode of administration.

• A. Eptinezumab by intravenous infusion; Galcanezumab by monthly SC
• B. Erenumab (Aimovig) by monthly subcutaneous injection; Fremanezumab (Ajovy) by monthly or quarterly subcutaneous injections
• C. Erenumab by oral daily; Fremanezumab by intravenous injections
• D. Galcanezumab by intramuscular; Erenumab by oral

Answer: (B)

CGRP pathway blocking antibodies used for migraine prevention are monoclonal antibodies that inhibit CGRP signaling, and they are given by subcutaneous injection. Erenumab (Aimovig) is administered as a monthly subcutaneous injection. Fremanezumab (Ajovy) is given by subcutaneous injections as either monthly or quarterly dosing. This combination highlights the common administration route and flexible dosing schedules for these preventive therapies. Other options mention routes like intravenous infusion or oral administration, which are not how these two agents are routinely given.

CGRP pathway blocking antibodies used for migraine prevention are monoclonal antibodies that inhibit CGRP signaling, and they are given by subcutaneous injection. Erenumab (Aimovig) is administered as a monthly subcutaneous injection. Fremanezumab (Ajovy) is given by subcutaneous injections as either monthly or quarterly dosing. This combination highlights the common administration route and flexible dosing schedules for these preventive therapies. Other options mention routes like intravenous infusion or oral administration, which are not how these two agents are routinely given.